Get the Stockscreener App
28.29
0.28%
0.08
After Hours:
28.57
0.28
+0.99%
Royalty Pharma Plc stock is traded at $28.29, with a volume of 1.23M.
It is up +0.28% in the last 24 hours and down -2.55% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$28.21
Open:
$28.25
24h Volume:
1.23M
Relative Volume:
0.52
Market Cap:
$12.64B
Revenue:
$2.24B
Net Income/Loss:
$673.24M
P/E Ratio:
251.47
EPS:
0.1125
Net Cash Flow:
$2.67B
1W Performance:
+2.09%
1M Performance:
-2.55%
6M Performance:
-6.85%
1Y Performance:
+4.24%
1-Day Range:
$28.06
$28.36
1-Week Range:
$27.56
$28.50
52-Week Range:
$25.20
$31.66
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Squarepoint Ops LLC - MarketBeat
Thrivent Financial for Lutherans Has $4.60 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma announces FDA approval milestone By Investing.com - Investing.com Canada
Royalty Pharma announces FDA approval milestone - Investing.com
Employees Retirement System of Texas Makes New Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Amalgamated Bank Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
BIIB: 3 Biotech Stocks Wall Street Predicts Will Skyrocket - StockNews.com
Inspire Investing LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
AE Wealth Management LLC Buys New Shares in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Evergreen Capital Management LLC Increases Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Hsbc Holdings PLC Reduces Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Evergreen Capital Management LLC - MarketBeat
Canada Pension Plan Investment Board Has $20.69 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Long Term Trading Analysis for (RPRX) - Stock Traders Daily
Elo Mutual Pension Insurance Co Trims Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Simplify Asset Management Inc. Reduces Stake in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Tredje AP fonden Has $2.70 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Simplify Asset Management Inc. Trims Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Acadian Asset Management LLC Invests $250,000 in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Is Royalty Pharma plc (RPRX) the Best Affordable Stock To Buy Right Now? - Insider Monkey
StockNews.com Upgrades Royalty Pharma (NASDAQ:RPRX) to “Buy” - Defense World
Royalty Pharma’s $150 Million Royalty Funding Agreement with Ascendis Pharma - Global Legal Chronicle
Royalty Pharma plc's (NASDAQ:RPRX) Has Performed Well But Fundamentals Look Varied: Is There A Clear Direction For The Stock? - Simply Wall St
Meeder Advisory Services Inc. Increases Stake in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Menlo Advisors LLC Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
StockNews.com Upgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by State of New Jersey Common Pension Fund D - Defense World
Metric Analysis: Royalty Pharma plc (RPRX)’s Key Ratios in the Limelight - The Dwinnex
DekaBank Deutsche Girozentrale Cuts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Dai ichi Life Insurance Company Ltd Takes $2.48 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Daiwa Securities Group Inc. Boosts Stake in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade - The Motley Fool
Forsta AP Fonden Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Royal London Asset Management Ltd. - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Forsta AP Fonden - MarketBeat
TD Asset Management Inc Decreases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Principal Financial Group Inc. - Defense World
Victory Capital Management Inc. Has $17.66 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Main Street Financial Solutions LLC Makes New $1.20 Million Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Rhumbline Advisers Sells 11,165 Shares of Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Prudential PLC Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) On The My Stocks Page - Stock Traders Daily
Royalty Pharma (NASDAQ:RPRX) Lowered to Hold at StockNews.com - Defense World
StockNews.com Lowers Royalty Pharma (NASDAQ:RPRX) to Hold - MarketBeat
Latham & Watkins Advises Ascendis Pharma in US$150 Million Royalty Financing - Legal Desire News Network
Los Angeles Capital Management LLC Reduces Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Los Angeles Capital Management LLC Has $11.75 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Van ECK Associates Corp Grows Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
New South Capital Management Inc. Purchases 887,522 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):